ClinVar Miner

Submissions for variant NM_001365951.3(KIF1B):c.1765A>G (p.Asn589Asp)

gnomAD frequency: 0.00001  dbSNP: rs1415991152
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001071436 SCV001236742 uncertain significance Charcot-Marie-Tooth disease type 2 2019-02-24 criteria provided, single submitter clinical testing This sequence change replaces asparagine with aspartic acid at codon 543 of the KIF1B protein (p.Asn543Asp). The asparagine residue is weakly conserved and there is a small physicochemical difference between asparagine and aspartic acid. This variant is not present in population databases (ExAC no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The aspartic acid amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with KIF1B-related conditions.
Ambry Genetics RCV002402487 SCV002708677 uncertain significance Hereditary cancer-predisposing syndrome 2021-02-10 criteria provided, single submitter clinical testing The p.N543D variant (also known as c.1627A>G), located in coding exon 16 of the KIF1B gene, results from an A to G substitution at nucleotide position 1627. The asparagine at codon 543 is replaced by aspartic acid, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.